Oxford/AstraZeneca Third Booster Strong Enough Against COVID-19 Variants, Study Shows: FT
- Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported citing people familiar with the matter.
- A third booster shot showed "strong enough against any variant," despite concern that the immune system might fight off the adenovirus used as a delivery mechanism.
- Some scientists have feared that repeated use of the adenovirus vector - an inactivated cold virus - could stop the immune system from recognizing the virus's spike protein.
- However, the study found the participants' immune systems reacted to the adenovirus used to deliver the protein. Still, it had a far more significant reaction to the protein, according to the FT.
- It is not known when Oxford and AstraZeneca plan to publish study data, the paper added.
- Price Action: AZN shares are up 0.21% at $56.11 during the premarket session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs COVID-19 Vaccine Financial TimesBiotech News Health Care General Best of Benzinga
